ReproNovo Named to 2026 Fierce 15 Biotech List
The Swiss biotech firm was recognized for its innovative work in fertility and women's health.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you trust that current fertility and women's health research is meeting your medical needs?
ReproNovo has been selected as one of the 2026 Fierce 15 biotech companies by Fierce Biotech. The Lausanne-based firm was chosen for its commitment to addressing significant gaps in fertility and women's health treatments.
Why it matters
The recognition highlights the company's progress in developing specialized therapies like RPN-001 and RPN-002. It serves as a benchmark for the firm's standing in global venture backing and market positioning.
ReproNovo is advancing RPN-001 for male infertility and RPN-002 for female fertility and adenomyosis. The company currently conducts multi-region clinical trials across the U.S., Europe, and China.
The players
ReproNovo
A biotechnology company headquartered in Lausanne, Switzerland, that focuses on fertility and women's health.
Fierce Biotech
An industry publication that has published its annual list of 15 notable private biotechnology companies for 24 years.
The details
Fierce Biotech evaluated hundreds of global candidates based on their technology, partnerships, and market position to finalize this year's list. ReproNovo maintains a distributed development model with teams operating out of Copenhagen and Barcelona.
Timeline
Fierce Biotech announced the 2026 Fierce 15 list on October 5, 2026.
The Tech Race
This selection underscores a broader industry shift toward specialized reproductive medicine and targeted fertility therapies. It positions the company within a competitive landscape of startups vying for market share in global women's health.
The firm's ongoing clinical trials represent a potential future expansion of available treatment options for couples struggling with infertility. Patients and medical providers may soon have access to new therapeutic pathways pending trial success and regulatory approval.
The takeaway
The selection of ReproNovo signals increasing investor confidence in the niche sector of reproductive biotechnology. Companies reaching this level of visibility often leverage the recognition to scale clinical operations and accelerate product development.
Further reading
For more on emerging research in this field, explore our Biotech section.
More information
Learn more about the company's research pipeline on the ReproNovo company website.
Live Poll
Do you trust that current fertility and women's health research is meeting your medical needs?
